Abu Dhabi Ship Building Signs MoU with PT PAL Indonesia

Abu Dhabi Ship Building Signs MoU with PT PAL Indonesia
TT

Abu Dhabi Ship Building Signs MoU with PT PAL Indonesia

Abu Dhabi Ship Building Signs MoU with PT PAL Indonesia

Abu Dhabi Ship Building (ADSB) signed a Memorandum of Understanding with PT PAL Indonesia to strengthen cooperation and to leverage the capabilities of both partners to build a range of interceptors, landing craft, and rigid-hull inflatable boats (RHIBs) for Indonesia’s naval and coast guard requirements.

The deal was signed by Maktoom Al Shehhi, Director of MRO at ADSB; and Dr. Kaharuddin Djenod, CEO of PT PAL Indonesia, on the second day of the Indo Defense Expo & Forum 2022, held at JIExpo Kemayoran in Jakarta, Indonesia, until 5th November.

Commenting on the deal, CEO of ADSB David Massey said: “Our cooperation with PT PAL clearly strengthens our investment in Indonesia and the global export success of our world-class vessels."

“We are very pleased to be working with PT PAL, and we look forward to jointly pursuing opportunities that will help to achieve our respective business and national objectives.”

For his part, Dr. Kaharuddin Djenod, CEO of PT PAL Indonesia, said: “We are pleased to sign this MoU with Abu Dhabi Ship Building, which will support our objective of strengthening the Indonesian naval and defence industry. This collaboration will strengthen PT PAL's role in mastering naval technology in Indonesia."



UAE’s Mubadala Acquires Majority Stakes in Global Medical Supply Chain, Al Ittihad Drug

The acquisition enhances Mubadala's footprint in the healthcare logistics and pharmaceutical distribution sectors. WAM
The acquisition enhances Mubadala's footprint in the healthcare logistics and pharmaceutical distribution sectors. WAM
TT

UAE’s Mubadala Acquires Majority Stakes in Global Medical Supply Chain, Al Ittihad Drug

The acquisition enhances Mubadala's footprint in the healthcare logistics and pharmaceutical distribution sectors. WAM
The acquisition enhances Mubadala's footprint in the healthcare logistics and pharmaceutical distribution sectors. WAM

Mubadala Investment Company has acquired an 80% stake in Global Medical Supply Chain (GMSC) and Al Ittihad Drug Store (IDS) from GlobalOne Healthcare Holding (GHH), with GHH retaining a 20% stake, Emirates News Agency (WAM) reported on Tuesday.

This strategic acquisition enhances Mubadala's footprint in the healthcare logistics and pharmaceutical distribution sectors, aligning with the UAE's vision to establish a robust life sciences infrastructure, WAM said.

Founded in 2015, GMSC provides comprehensive end-to-end supply chain services for medical products, including demand planning, procurement, logistics, inventory management, warehousing, and maintenance.

GMSC serves over 200 medical facilities, including hospitals and clinics across the UAE. With a dedicated team of medical supply chain specialists, GMSC sources a broad array of products from almost 400 suppliers, ensuring a reliable supply chain for all medical needs.

IDS, established in 1987, stands as one of the leading distributors of pharmaceutical and consumer healthcare products in the UAE. Distributing over 1,000 products from over 40 leading suppliers, IDS services every hospital, and all, or at least most pharmacies and supermarkets within the UAE. It boasts a vast portfolio that spans multiple therapeutic categories including anti-infectives, asthma, diabetes, and oncology.

"The expanding pharmaceutical market drives an increasing demand for specialized and efficient drug logistics solutions. By integrating GMSC and IDS into our portfolio, we are poised to create a vertically integrated life sciences sector in the UAE and enable its potential to encompass the entire value chain from logistics and distribution to specialized manufacturing,” said Executive Director of UAE Clusters at Mubadala's UAE Investments Platform Ismail Ali Abdulla.

As for Low Ping, Group CEO Yas Holding, she said that the transaction “continues Mubadala's strategic growth, following another significant acquisition by its new speciality pharmaceutical business, KELIX bio, which recently acquired a 100% stake in four pharma assets from GlobalOne Healthcare Holding's, the healthcare division of Yas Holding.”

“These concerted efforts underline Mubadala's commitment to strengthening the UAE's healthcare and pharmaceutical sectors as part of broader national ambitions for drug security and economic diversification."

GlobalOne Healthcare Holding LLC serves as the dedicated Healthcare Division of Yas Holding LLC, focusing on enhancing healthcare outcomes by investing in innovative solutions across various healthcare verticals.